Molecular imaging of apoptosis for early prediction of therapy efficiency

Current Pharmaceutical Design

Volumn 20, Issue 14, 2014, Pages 2319-2328

  De Saint Hubert, Marijke ^a,b   Bauwens, Matthias ^a,c   Mottaghy, Felix M ^a,d  

^a Nuclear Medicine MUMC+   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Apoptosis; Early cancer therapy evaluation; Molecular imaging

Indexed keywords

FLUORINE 18; ISATIN; LIPOCORTIN 5; SYNAPTOTAGMIN; TECHNETIUM 99M; TRACER; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

APOPTOSIS; ARTICLE; CARCINOGENESIS; HUMAN; MOLECULAR IMAGING; MOLECULAR MECHANICS; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; DRUG EFFECTS; NEOPLASMS; PHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROTEIN SECONDARY STRUCTURE; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MOLECULAR IMAGING; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN STRUCTURE, SECONDARY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84903716642     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660664     Document Type: Article

References (64)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Colvin OM. An overview of cyclophosphamide development and clinical applications. Curr Pharm Des 1999; 5: 555-60.
3. Pilgrim CH, Satgunaseelan L, Pham A, et al. Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity. HPB (Oxford) 2012; 14: 333-40.
4. Pilgrim CH, Thomson BN, Banting S, Phillips WA, Michael M. The developing clinical problem of chemotherapy-induced hepatic injury. ANZ J Surg 2012; 82: 23-9.
5. Zygulska AL, Krzemieniecki K. Cardiological adverse events after oncological treatment in women. Przegl Lek 2012; 69: 87-9.
6. Nguyen QD, Aboagye EO. Imaging the life and death of tumors in living subjects: Preclinical PET imaging of proliferation and apoptosis. Integr Biol (Camb); 2: 483-95.
7. Breckenridge DG, Xue D. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr Opin Cell Biol 2004; 16: 647-52.
8. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-73.
9. Adachi M, Imai K. The proapoptotic BH3-only protein BAD transduces cell death signals independently of its interaction with Bcl-2. Cell Death Differ 2002; 9: 1240-7.
10. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705-11.
11. Buechler C, Bared SM, Aslanidis C, et al. Molecular and functional interaction of the ATP-binding cassette transporter A1 with Fasassociated death domain protein. J Biol Chem 2002; 277: 41307-10.
12. Miyake K, Bekisz J, Zhao T, Clark CR, Zoon KC. Apoptosisinducing factor (AIF) is targeted in IFN-alpha2a-induced Bidmediated apoptosis through Bak activation in ovarian cancer cells. Biochim Biophys Acta 2012; 1823: 1378-88.
13. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-16.
14. Emoto K, Toyama-Sorimachi N, Karasuyama H, Inoue K, Umeda M. Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp Cell Res 1997; 232: 430-4.
15. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-41.
16. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183-90.
17. Winfield LL, Payton-Stewart F. Celecoxib and Bcl-2: emerging possibilities for anticancer drug design. Future Med Chem 2012; 4: 361-83.
18. Kho ME, Brouwers MC. Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: rituximab for non-Hodgkin's lymphoma. J Clin Epidemiol 2012; 65: 996-1009.
19. Gori B, Ricciardi S, del Signore E, Fulvi A, de Marinis F. Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets 2012; 16 Suppl 2: S55-60.
20. Velho TR, Kapiteijn E, Jager MJ. New therapeutic agents in uveal melanoma. Anticancer Res 2012; 32: 2591-8.
21. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosisinducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-8.
22. Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 2006; 12: 382-93.
23. Blankenberg FG. In vivo detection of apoptosis. J Nucl Med 2008; 49 Suppl 2: 81S-95S.
24. Pauwels EK, Ribeiro MJ, Stoot JH, et al. FDG accumulation and tumor biology. Nucl Med Biol 1998; 25: 317-22.
25. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
26. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-56.
27. Koopman G, Reutelingsperger CP, Kuijten GA, et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-20.
28. Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 1999; 40: 184-91.
29. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998; 95: 6349-54.
30. Tait JF, Smith C, Levashova Z, et al. Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J Nucl Med 2006; 47: 1546-53.
31. De Saint-Hubert M, Mottaghy FM, Vunckx K, et al. Site-specific labeling of 'second generation' annexin V with 99mTc(CO)3 for improved imaging of apoptosis in vivo. Bioorg Med Chem; 18: 1356-63.
32. Tait JF, Brown DS, Gibson DF, Blankenberg FG, Strauss HW. Development and characterization of annexin V mutants with endogenous chelation sites for (99m)Tc. Bioconjug Chem 2000; 11: 918-25.
33. Lahorte CM, Vanderheyden JL, Steinmetz N, et al. Apoptosisdetecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004; 31: 887-919.
34. Wuest F, Berndt M, Bergmann R, van den Hoff J, Pietzsch J. Synthesis and application of [18F]FDG-maleimidehexyloxime ([18F]FDG-MHO): a [18F]FDG-based prosthetic group for the chemoselective 18F-labeling of peptides and proteins. Bioconjug Chem 2008; 19: 1202-10.
35. Zijlstra S, Gunawan J, Burchert W. Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl Radiat Isot 2003; 58: 201-7.
36. Li X, Link JM, Stekhova S, et al. Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug Chem 2008; 19: 1684-8.
37. Yagle KJ, Eary JF, Tait JF, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005; 46: 658-66.
38. Bauwens M, De Saint-Hubert M, Devos E, et al. Site-specific 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl Med Biol; 38: 381-92.
39. Zhao M, Zhu X, Ji S, et al. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J Nucl Med 2006; 47: 1367-74.
40. Zhou D, Chu W, Rothfuss J, et al. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 2006; 16: 5041-6.
41. Chen DL, Zhou D, Chu W, et al. Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. Nucl Med Biol 2009; 36: 651-8.
42. Smith G, Glaser M, Perumal M, et al. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem 2008; 51: 8057-67.
43. Nguyen QD, Challapalli A, Smith G, Fortt R, Aboagye EO. Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11. Eur J Cancer 2012; 48: 432-40.
44. Kolb HW, J.; Gangadharmath, U.; Mu, F.; Mocharla, V.; Chaudhary, A.; Chen, G; Chen, K.; Szardenings, K. In SNM 2011; J Nucl Med 2011; 52: 1430.
45. Nguyen QD, Smith G, Glaser M, et al. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci USA 2009; 106: 16375-80.
46. Grimberg H, Levin G, Shirvan A, et al. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 2009; 14: 257-67.
47. Bauwens, M.; De Saint-Hubert M.; Cleynhens, J.; Devos, E., Deckers, N.; Reutelingsperger, C.; Verbruggen A. In Euroconference on apoptosis: Ghent, 2010.
48. Bauwens M, De Saint-Hubert M, Cleynhens J, et al. Radioiodinated Phenylalkyl Malonic Acid Derivatives as pH-Sensitive SPECT Tracers. PLoS One 2012; 7: e38428.
49. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
50. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-9.
51. Brepoels L, De Saint-Hubert M, Stroobants S, et al. Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging 2010; 37: 1688-95.
52. Brepoels L, Stroobants S, Vandenberghe P, et al. Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy. J Nucl Med 2007; 48: 390-7.
53. Nishimura Y, Hirabayashi Y, Matsuzaki Y, et al. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol 1997; 9: 307-16.
54. Ledda-Columbano GM, Coni P, Faa G, Manenti G, Columbano A. Rapid induction of apoptosis in rat liver by cycloheximide. Am J Pathol 1992; 140: 545-9.
55. Takei T, Kuge Y, Zhao S, et al. Time course of apoptotic tumor response after a single dose of chemotherapy: comparison with 99mTc-annexin V uptake and histologic findings in an experimental model. J Nucl Med 2004; 45: 2083-7.
56. Takei T, Kuge Y, Zhao S, et al. Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation. J Nucl Med 2005; 46: 794-9.
57. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002; 8: 2766-74.
58. Kartachova M, van Zandwijk N, Burgers S, et al. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol 2007; 25: 2534-9.
59. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 2004; 59: 782-7.
60. Verheij M. Clinical biomarkers and imaging for radiotherapyinduced cell death. Cancer Metastasis Rev 2008; 27: 471-80.
61. De Saint-Hubert M, Wang H, Devos E, et al. Preclinical imaging of therapy response using metabolic and apoptosis molecular imaging. Mol Imaging Biol 2011; 13: 995-1002.
62. Vangestel C, Van de Wiele C, Van Damme N, et al. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. J Nucl Med 2011; 52: 1786-94.
63. Wang F, Fang W, Zhao M, et al. Imaging paclitaxel (chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I: a preliminary study. Nucl Med Biol 2008; 35: 359-64.
64. Evaluation of [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Whole Brain Radiation Therapy. http://clinicaltrials.gov/ct2/show/NCT00791063.